U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT06870942) titled 'Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy' on March 04.
Brief Summary: Immune checkpoint inhibitors (ICIs) have significantly improved the survival outcomes of HCC patients. However, a considerable proportion of patients eventually experience disease progression due to the development of resistance. Among these, oligoprogression is a common manifestation, occurring in 10-55.3% of advanced cancer patients. Local therapy, especially radiotherapy (RT), has been increasingly considered in the setting of oligoprogression to overcome ICIs resistance and delay the need to change systemic...